Safety and effectiveness of RBD-specific polyclonal equine F(ab´)(2) fragments for the treatment of hospitalized patients with severe Covid-19 disease: A retrospective cohort study

BACKGROUND: Passive immunotherapy has been evaluated as a therapeutic alternative for patients with COVID-19 disease. Equine polyclonal immunotherapy for COVID-19 (EPIC) showed adequate safety and potential efficacy in a clinical trial setting and obtained emergency use authorization in Argentina. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Farizano Salazar, Diego H., Achinelli, Fernando, Colonna, Mariana, Pérez, Lucía, Giménez, Analía A., Ojeda, Maria Alejandra, Miranda Puente, Susana N., Sánchez Negrette, Lía, Cañete, Florencia, Martelotte Ibarra, Ornela I., Sanguineti, Santiago, Spatz, Linus, Goldbaum, Fernando A., Massa, Carolina, Rivas, Marta, Pichel, Mariana, Hiriart, Yanina, Zylberman, Vanesa, Gallego, Sandra, Konigheim, Brenda, Fernández, Francisco, Deprati, Matías, Roubicek, Ian, Giunta, Diego H., Nannini, Esteban, Lopardo, Gustavo, Belloso, Waldo H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512184/
https://www.ncbi.nlm.nih.gov/pubmed/36155545
http://dx.doi.org/10.1371/journal.pone.0274796

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512184/
https://www.ncbi.nlm.nih.gov/pubmed/36155545
http://dx.doi.org/10.1371/journal.pone.0274796

Ejemplares similares